|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peto R: The fraction of cancer
attributable to lifestyle and environmental factors in the UK in
2010. Br J Cancer. 105 (Suppl 2):S12011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y, Yang G, You L, Yang J, Feng M, Qiu
J, Zhao F, Liu Y, Cao Z, Zheng L, et al: Role of the microbiome in
occurrence, development and treatment of pancreatic cancer. Mol
Cancer. 18:1732019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chu LC, Goggins MG and Fishman EK:
Diagnosis and detection of pancreatic cancer. Cancer J. 23:333–342.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quaresma M, Coleman MP and Rachet B:
40-year trends in an index of survival for all cancers combined and
survival adjusted for age and sex for each cancer in England and
Wales, 1971-2011: A population-based study. Lancet. 385:1206–1218.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raimondi S, Maisonneuve P and Lowenfels
AB: Epidemiology of pancreatic cancer: An overview. Nat Rev
Gastroenterol Hepatol. 6:699–708. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsui CC, Copeland NG, Gilbert DJ, Jenkins
NA, Barnes C and Worley PF: Narp, a novel member of the pentraxin
family, promotes neurite outgrowth and is dynamically regulated by
neuronal activity. J Neurosci. 16:2463–2478. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schlimgen AK, Helms JA, Vogel H and Perin
MS: Neuronal pentraxin, a secreted protein with homology to acute
phase proteins of the immune system. Neuron. 14:519–526. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hagihara A, Miyamoto K, Furuta J, Hiraoka
N, Wakazono K, Seki S, Fukushima S, Tsao MS, Sugimura T and
Ushijima T: Identification of 27 5′ CpG islands aberrantly
methylated and 13 genes silenced in human pancreatic cancers.
Oncogene. 23:8705–8710. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng X, Pan K, Zhao W, Zhang J, Yuan S,
Wen X, Zhou W and Yu Z: NPTX1 inhibits colon cancer cell
proliferation through down-regulating cyclin A2 and CDK2
expression. Cell Biol Int. 42:589–597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou C, Qin Y, Xie Z, Zhang J, Yang M, Li
S and Chen R: NPTX1 is a novel epigenetic regulation gene and
associated with prognosis in lung cancer. Biochem Biophys Res
Commun. 458:381–386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yue W, Wang T, Zachariah E, Lin Y, Yang
CS, Xu Q, DiPaola RS and Tan XL: Transcriptomic analysis of
pancreatic cancer cells in response to metformin and aspirin: An
implication of synergy. Sci Rep. 5:133902015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yue W, Yang CS, DiPaola RS and Tan XL:
Repurposing of metformin and aspirin by targeting AMPK-mTOR and
inflammation for pancreatic cancer prevention and treatment. Cancer
Prev Res (Phila). 7:388–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mini E, Nobili S, Caciagli B, Landini I
and Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol. 17
(Suppl 5):v7–v12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heinemann V: Gemcitabine: Progress in the
treatment of pancreatic cancer. Oncology. 60:8–18. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Ni Q, Jin M, Li Z, Wu Y, Zhao Y
and Feng F: Gemcitabine or gemcitabine plus cisplatin for in 42
patients with locally advanced or metastatic pancreatic cancer.
Zhonghua Zhong Liu Za Zhi. 24:404–407. 2002.PubMed/NCBI
|
|
18
|
Thiselton DL, McDowall J, Brandau O,
Ramser J, d'Esposito F, Bhattacharya SS, Ross MT, Hardcastle AJ and
Meindl A: An integrated, functionally annotated gene map of the
DXS8026-ELK1 interval on human Xp11.3-Xp11.23: Potential hotspot
for neurogenetic disorders. Genomics. 79:560–572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao J, Sun Y, Huang Y, Song F, Huang Z,
Bao Y, Zuo J, Saffen D, Shao Z, Liu W and Wang Y: Functional
analysis reveals that RBM10 mutations contribute to lung
adenocarcinoma pathogenesis by deregulating splicing. Sci Rep.
7:404882017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang K, Bacon ML, Tessier JJ, Rintala-Maki
ND, Tang V and Sutherland LC: RBM10 modulates apoptosis and
influences TNF-α gene expression. J Cell Death. 5:1–19. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao W, Chen X, Li X, Deng K, Liu H, Ma J,
Wang Z, Hu Y and Hou J: RBM10 regulates human TERT gene splicing
and inhibits pancreatic cancer progression. Am J Cancer Res.
11:157–170. 2021.PubMed/NCBI
|
|
22
|
Zhao Y, Yu Y, Zhao W, You S, Feng M, Xie
C, Chi X, Zhang Y and Wang X: As a downstream target of the AKT
pathway, NPTX1 inhibits proliferation and promotes apoptosis in
hepatocellular carcinoma. Biosci Rep. 39:BSR201816622019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin X, Di X, Wang R, Ma H, Tian C, Zhao M,
Cong S, Liu J, Li R and Wang K: RBM10 inhibits cell proliferation
of lung adenocarcinoma via RAP1/AKT/CREB signalling pathway. J Cell
Mol Med. 23:3897–3904. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Previdi MC, Carotenuto P, Zito D, Pandolfo
R and Braconi C: Noncoding RNAs as novel biomarkers in pancreatic
cancer: What do we know? Future Oncol. 13:443–453. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gedge K: Pancreatic cancer: A symptomless
killer. J Perioper Pract. 27:158–161. 2017.PubMed/NCBI
|
|
28
|
Boles NC, Hirsch SE, Le S, Corneo B, Najm
F, Minotti AP, Wang Q, Lotz S, Tesar PJ and Fasano CA: NPTX1
regulates neural lineage specification from human pluripotent stem
cells. Cell Rep. 6:724–736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu S, Zhou C, Zou B, Zhang H and Feng M:
MiR-4295 facilitates cell proliferation and metastasis in head and
neck squamous cell carcinoma by targeting NPTX1. Genes Immun.
21:4–12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miao H, Chen X and Luan Y: Small molecular
gemcitabine prodrugs for cancer therapy. Curr Med Chem.
27:5562–5582. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abrams TJ, Lee LB, Murray LJ, Pryer NK and
Cherrington JM: SU11248 inhibits KIT and platelet-derived growth
factor receptor beta in preclinical models of human small cell lung
cancer. Mol Cancer Ther. 2:471–478. 2003.PubMed/NCBI
|
|
33
|
Koch M, Krieger ML, Stölting D, Brenner N,
Beier M, Jaehde U, Wiese M, Royer HD and Bendas G: Overcoming
chemotherapy resistance of ovarian cancer cells by liposomal
cisplatin: Molecular mechanisms unveiled by gene expression
profiling. Biochem Pharmacol. 85:1077–1090. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Steinberg RL, Thomas LJ, Brooks N, Mott
SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, et
al: Multi-institution evaluation of sequential gemcitabine and
docetaxel as rescue therapy for nonmuscle invasive bladder cancer.
J Urol. 203:902–909. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seidman AD: Gemcitabine as single-agent
therapy in the management of advanced breast cancer. Oncology
(Williston Park). 15 (2 Suppl 3):S11–S14. 2001.
|
|
36
|
Jackson TC, Du L, Janesko-Feldman K, Vagni
VA, Dezfulian C, Poloyac SM, Jackson EK, Clark RS and Kochanek PM:
The nuclear splicing factor RNA binding motif 5 promotes caspase
activation in human neuronal cells, and increases after traumatic
brain injury in mice. J Cereb Blood Flow Metab. 35:655–666. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Loiselle JJ and Sutherland LC:
Differential downregulation of Rbm5 and Rbm10 during skeletal and
cardiac differentiation. In Vitro Cell Dev Biol Anim. 50:331–339.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodor J, FitzPatrick DR, Eyras E and
Cáceres JF: The RNA-binding landscape of RBM10 and its role in
alternative splicing regulation in models of mouse early
development. RNA Biol. 14:45–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Minaga K, Watanabe T, Hara A, Kamata K,
Omoto S, Nakai A, Otsuka Y, Sekai I, Yoshikawa T, Yamao K, et al:
Identification of serum IFN-α and IL-33 as novel biomarkers for
type 1 autoimmune pancreatitis and IgG4-related disease. Sci Rep.
10:148792020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fujisawa M, Kanda T, Shibata T, Sasaki R,
Masuzaki R, Matsumoto N, Nirei K, Imazu H, Kuroda K, Sugitani M, et
al: Involvement of the interferon signaling pathways in pancreatic
cancer cells. Anticancer Res. 40:4445–4455. 2020. View Article : Google Scholar : PubMed/NCBI
|
